BPMC

Blueprint Medicines to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 15, 2024

Retrieved on: 
Thursday, February 1, 2024
Webcast, BPMC, ID

CAMBRIDGE, Mass., Feb. 1, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m.

Key Points: 
  • CAMBRIDGE, Mass., Feb. 1, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m.
  • ET on Thursday, February 15, 2024, to report its fourth quarter and full year 2023 financial results and provide a corporate update.
  • A webcast of the call will also be available under "Events and Presentations" in the Investors & Media section of the Blueprint Medicines website at http://ir.blueprintmedicines.com/ .
  • The archived webcast will be available on Blueprint Medicines' website approximately two hours after the conference call and will be available for 30 days following the call.

Blueprint Medicines Highlights 2024 Corporate Strategy and Business Priorities at 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Monday, January 8, 2024
Biology, Marketing, Conference, Partnership, ISM, CDK2, IND, Breast cancer, Fulvestrant, Research, B cell, Lung, Roche, KIT, SAN, Q&A, J. P. Morgan, Growth, Investment, Patient, Webcast, Safety, BPMC, Medicine, NSCLC, Mastocytosis, Pharmaceutical industry

SAN FRANCISCO, Jan. 8, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today outlined its 2024 corporate strategy to deliver accelerated revenue growth, sustainable research and development, and a clear path to profitability.

Key Points: 
  • ET) --
    SAN FRANCISCO, Jan. 8, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today outlined its 2024 corporate strategy to deliver accelerated revenue growth, sustainable research and development, and a clear path to profitability.
  • As a result of continued strategic portfolio prioritization, Blueprint Medicines expects a year-over-year decline in operating expenses in 2024.
  • Kate Haviland, Chief Executive Officer of Blueprint Medicines, will present a company overview and 2024 outlook at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8 at 10:30 a.m. PT / 1:30 p.m.
  • A replay of the webcast will be archived on Blueprint Medicines' website for 30 days following the presentation.

Blueprint Medicines' Leadership in Driving Continued Innovation in Systemic Mastocytosis Highlighted at 2023 ASH Annual Meeting

Retrieved on: 
Saturday, December 9, 2023
BPMC, ASH, Aes, Disease, Patient, ISM, Survival, Society, Pharmaceutical industry

CAMBRIDGE, Mass., Dec. 9, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced data showcasing its commitment to advance the scientific understanding and treatment of systemic mastocytosis (SM) at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 9-12 in San Diego. Data that will be presented include results from the HARBOR Part 1 trial of elenestinib in indolent systemic mastocytosis (ISM) and analyses of real-world data highlighting the burden of and urgency to treat ISM.

Key Points: 
  • Data that will be presented include results from the HARBOR Part 1 trial of elenestinib in indolent systemic mastocytosis (ISM) and analyses of real-world data highlighting the burden of and urgency to treat ISM.
  • HARBOR Part 1 trial data in patients with ISM showed elenestinib was well-tolerated and clinically active at all dose levels tested, supporting further development.
  • In patients treated with elenestinib, most adverse events (AEs) were Grade 1 or 2, and there were no discontinuations due to AEs.
  • At ASH, new data on the burden of disease highlight the urgency to treat patients with ISM.

Blueprint Medicines to Present at JMP Securities Hematology and Oncology Summit

Retrieved on: 
Tuesday, November 28, 2023
BPMC, Webcast, Hematology, Online shopping

CAMBRIDGE, Mass., Nov. 28, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced that company management will participate virtually in a fireside chat at the JMP Securities Hematology and Oncology Summit on Tuesday, December 5, 2023 at 11:00 a.m.

Key Points: 
  • CAMBRIDGE, Mass., Nov. 28, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced that company management will participate virtually in a fireside chat at the JMP Securities Hematology and Oncology Summit on Tuesday, December 5, 2023 at 11:00 a.m.
  • ET.
  • A live webcast of the presentation will be available by visiting the Investors & Media section of Blueprint Medicines' website at http://ir.blueprintmedicines.com .
  • A replay of the webcast will be archived on Blueprint Medicines' website for 30 days following the presentation.

Anixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr. Mark A. Goldberg, to Cancer Business Advisory Board

Retrieved on: 
Monday, October 23, 2023
American Cancer Society, Harvard–MIT Program in Health Sciences and Technology, Bachelor of Arts, Harvard Medical School, Brigham and Women's Hospital, IMGN, Genzyme, Biotechnology, ImmunoGen, MD, Drug, Harvard College, Senior, Medicine, Synageva, CBAB, ACS, LSE, Cancer, Hospital, BPMC, SAN, Management, Glycomimetic

SAN JOSE, Calif., Oct. 23, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has appointed Mark A. Goldberg, MD, to its Cancer Business Advisory Board (CBAB).

Key Points: 
  • SAN JOSE, Calif., Oct. 23, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has appointed Mark A. Goldberg, MD, to its Cancer Business Advisory Board (CBAB).
  • "We are pleased to welcome Dr. Goldberg as the 9th independent member of our CBAB," said Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences.
  • "Mark brings valuable clinical expertise in oncology, and his extensive biotechnology executive experience will be an asset to Anixa.
  • Dr. Goldberg received his Bachelor of Arts degree from Harvard College and his medical degree from the Harvard-MIT Program in Health Sciences and Technology.

Blueprint Medicines to Report Third Quarter 2023 Financial Results on Thursday, October 26, 2023

Retrieved on: 
Thursday, October 12, 2023
ID, Webcast, BPMC, Rare-earth element, Video game

CAMBRIDGE, Mass., Oct. 12, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m.

Key Points: 
  • CAMBRIDGE, Mass., Oct. 12, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m.
  • ET on Thursday, October 26, 2023, to report its third quarter financial results and provide a corporate update.
  • A webcast of the call will also be available under "Events and Presentations" in the Investors & Media section of the Blueprint Medicines website at http://ir.blueprintmedicines.com/ .
  • The archived webcast will be available on Blueprint Medicines' website approximately two hours after the conference call and will be available for 30 days following the call.

Blueprint Medicines to Report Second Quarter 2023 Financial Results on Wednesday, August 2, 2023

Retrieved on: 
Wednesday, July 19, 2023
Webcast, BPMC, ID, Cryptocurrency, Video game

CAMBRIDGE, Mass., July 19, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m.

Key Points: 
  • CAMBRIDGE, Mass., July 19, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m.
  • ET on Wednesday, August 2, 2023, to report its second quarter financial results and provide a corporate update.
  • A webcast of the call will also be available under "Events and Presentations" in the Investors & Media section of the Blueprint Medicines website at http://ir.blueprintmedicines.com/ .
  • The archived webcast will be available on Blueprint Medicines' website approximately two hours after the conference call and will be available for 30 days following the call.

Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Wednesday, July 5, 2023
Employment, BPMC, RSU, Compensated emancipation, Pharmaceutical industry

CAMBRIDGE, Mass., July 5, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective July 1, 2023, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 13,093 shares of its common stock and an aggregate of 6,546 restricted stock units (RSUs) to four new employees under Blueprint Medicines' 2020 Inducement Plan.

Key Points: 
  • CAMBRIDGE, Mass., July 5, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective July 1, 2023, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 13,093 shares of its common stock and an aggregate of 6,546 restricted stock units (RSUs) to four new employees under Blueprint Medicines' 2020 Inducement Plan.
  • The 2020 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Blueprint Medicines, as an inducement material to such individual's entering into employment with Blueprint Medicines, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.
  • The options have an exercise price of $63.20 per share, which is equal to the closing price of Blueprint Medicines' common stock on June 30, 2023.
  • The options and RSUs are subject to the terms and conditions of Blueprint Medicines' 2020 Inducement Plan, and the terms and conditions of the stock option and RSU agreement covering the grant.

Blueprint Medicines Highlights Clinical Progress Across Precision Oncology Pipeline at 2023 ASCO Annual Meeting

Retrieved on: 
Saturday, June 3, 2023
DNA, Circulating tumor DNA, Central nervous system, BPMC, Neoplasm, Aes, RECIST, Cancer, Fulvestrant, PRB, First grade, SYMPHONY, History, CNS, Science, QT interval, ASCO, Malignancy, CDK2, American Society of Clinical Oncology, Ribociclib, TK1, Patient, EGFR, Annual general meeting, VELA, Society, Safety, Breast cancer, Medical imaging, Pharmaceutical industry, Flour, Mineral wool, NSCLC

CAMBRIDGE, Mass., June 3, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced clinical data for multiple programs across its precision therapy portfolio at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. The presentations showcase the company's progress in developing precision therapies to address the needs of broad patient populations, including hormone-receptor-positive/HER2-negative (HR+/HER2-) breast cancer and EGFR-mutant non-small cell lung cancer (NSCLC).

Key Points: 
  • -- Breadth of pipeline featured in multiple early clinical data presentations, reflecting diversity of fundamental growth drivers across development programs --
    CAMBRIDGE, Mass., June 3, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced clinical data for multiple programs across its precision therapy portfolio at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.
  • "At ASCO, we are reporting early clinical data for three therapeutic candidates highlighting the breadth of our pipeline, which lays the foundation for our next wave of precision therapy programs to tackle significant medical challenges," said Becker Hewes, M.D., Chief Medical Officer at Blueprint Medicines.
  • CDK2 is a cell cycle regulator and important cancer target across a broad range of malignancies, including HR+/HER2- breast cancer.
  • The data reported at ASCO begin to demonstrate the clinical profile of BLU-222, a highly selective and potent oral CDK2 inhibitor.

FDA Approves AYVAKIT® (avapritinib) as the First and Only Treatment for Indolent Systemic Mastocytosis

Retrieved on: 
Monday, May 22, 2023
Insurance, BPMC, University, Polypharmacy, Friends, Health care, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Quality of life, Hope, American Academy, Research, ID, Peripheral edema, ISM, SM, Patient, Dizziness, Annual general meeting, AAAAI, Webcast, Knowledge, FDA, Mental health, Family, Food, Flushing, Disease, Pharmaceutical industry, Vaccine, Medicine

CAMBRIDGE, Mass., May 22, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced that the U.S. Food and Drug Administration (FDA) has approved AYVAKIT® (avapritinib) for the treatment of adults with indolent systemic mastocytosis (ISM). All U.S. patients with ISM now have access to the first and only approved medicine designed to treat their disease.

Key Points: 
  • AYVAKIT has been FDA approved for the treatment of advanced SM since June 2021.
  • "AYVAKIT is the first and only medicine approved by the FDA to treat indolent systemic mastocytosis, marking a shift in the treatment paradigm from supportive care to disease modifying therapy.
  • In addition, AYVAKIT is the only treatment approved across the spectrum of indolent and advanced systemic mastocytosis.
  • "People with indolent systemic mastocytosis are significantly impacted by their disease symptoms, and many individuals self-isolate at home to protect against unpredictable external triggers.